Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Retatrutide , a triple agonist (GLP-1/GIP/glucagon), represents the next generation
Industry estimates suggest the company could lose as much as $17 billion in annual revenue from its existing portfolio by 2030
Retatrutide (LY3437943) is a synthetic peptide engineered to function as a multi-receptor signaling agonist within incretin-related metabolic pathways
One Hippo and many masters: differential regulation of the Hippo pathway in cancer
Research shows semaglutide significantly reduces waist circumference and waist-to-height ratio, indicating meaningful abdominal fat loss
US$ 25.10
US$ 23.56
US$ 28.70
US$ 24.15
US$ 29.34
US$ 25.36
US$ 26.58
US$ 20.40
US$ 26.49
US$ 20.70
US$ 26.00
US$ 21.98
